• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CATB

CATB

Catabasis Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD8.54

-0.64 (-6.97%)

Company Profile

CEO

Jill Milne

IPO Date

2015-06-25

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$10.07

Prev. Close

$9.18

Day Low

$8.48

Day High

$9.21

52W Low

$1.25

52W High

$10.26

Market Cap

$0.23B

Volume

0.10M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

27.8%

Avg Negative

11.5%

Avg Neutral

60.6%

News Feed

Catabasis Pharmaceuticals Shares: 1-For-6 Split Goes Into Effect

Pulse2·8/20/2021·↓ negative

CATB Stock Price Increases Over 40% Pre-Market: Why It Happened

Pulse2·6/16/2021·↑ positive

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

Business Wire·3/11/2021·↑ positive

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Business Wire·3/2/2021·↑ positive

CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today

InvestorPlace·1/29/2021·↑ positive

Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investors to Know

InvestorPlace·12/2/2020·↑ positive

Catabasis Pharmaceuticals News: Why CATB Stock Is Plummeting 69% Today

InvestorPlace·10/27/2020·↓ negative

SAB Biotherapeutics annonce le dosage du premier patient de l’essai clinique de phase 1b de SAB-185 pour le traitement du COVID-19

businesswire·8/22/2020·↑ positive

Dentistry – your ticket around the globe? Part three – Dentistry Online

https://www.dentistry.co.uk·8/14/2020·↑ positive

Catabasis Pharmaceuticals (CATB) Gets a Buy Rating from Oppenheimer - Markets

https://www.markets.co·8/11/2020·↑ positive